{{Short description|Chemical compound}} {{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = VK2809.svg | image_class = skin-invert-image | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = | ATCvet = | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = <!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US_comment = | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = <!-- For countries not listed above --> <!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = <!-- Identifiers --> | synonyms = VK-2809; MB07811 | CAS_number = 852948-13-1 | UNII = 3Z11398FNQ | PubChem = | DrugBank = DB15137 <!-- Chemical and physical data --> | IUPAC_name = (2''R'',4''S'')-4-(3-Chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2λ<sup>5</sup>-dioxaphosphinan-2-one | C=28 | H=32 | Cl=1 | O=5 | P=1 }}
'''VK2809''' (formerly known as '''MB07811''') is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis<ref>{{Cite web |title=VK2809 |url=https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2809/ |access-date=15 September 2023 |website=Viking Therapeutics}}</ref><ref>{{Cite journal |last=Alkhouri |first=Naim |date=1 February 2020 |title=Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) |journal=Expert Opinion on Investigational Drugs |language=en |volume=29 |issue=2 |pages=99–101 |doi=10.1080/13543784.2020.1708899 |issn=1354-3784 |doi-access=free|pmid=31868036 }}</ref> and is also being investigated for glycogen storage disease type Ia.<ref>{{Cite journal |last1=Zhou |first1=Jin |last2=Waskowicz |first2=Lauren R. |last3=Lim |first3=Andrea |last4=Liao |first4=Xiao-Hui |last5=Lian |first5=Brian |last6=Masamune |first6=Hiroko |last7=Refetoff |first7=Samuel |last8=Tran |first8=Brian |last9=Koeberl |first9=Dwight D. |last10=Yen |first10=Paul M. |date=1 August 2019 |title=A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia |journal=Thyroid |volume=29 |issue=8 |pages=1158–1167 |doi=10.1089/thy.2019.0007 |issn=1050-7256 |pmc=6707038 |pmid=31337282}}</ref>
In 2023, Viking Therapeutics filed a lawsuit against the developer of ASC41, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.<ref>{{cite news |title=Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache |url=https://www.fiercebiotech.com/biotech/viking-accuses-chinese-biotech-ruse-raid-trade-secrets-and-make-nash-cache |access-date=2 December 2023 |work=Fierce Biotech |date=3 January 2023}}</ref><ref>{{cite news | url = https://cen.acs.org/pharmaceuticals/drug-development/Viking-Therapeutics-accuses-competitor-pilfering/101/web/2023/01 | title = Viking Therapeutics accuses competitor of pilfering proprietary information | date = January 9, 2023 | publisher = Chemical & Engineering News | quote = Viking infers that ASC41 is Ascletis’s version of—if not the same compound as—VK2809 }}</ref>
==References== {{reflist}}
{{Thyroid hormone receptor modulators}}
Category:Thyroid hormone receptor beta agonists Category:Prodrugs Category:Dioxaphosphorinanes Category:Phenols Category:3-Chlorophenyl compounds Category:Isopropyl compounds Category:Experimental drugs developed for non-alcoholic fatty liver disease